CORRECTION -- uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

uniQure N.V. (NASDAQ: QURE) announced the granting of equity awards to 22 employees to incentivize their employment. The board approved the issuance of 39,500 restricted stock units (RSUs) and options for 27,500 ordinary shares at an exercise price of $14.08 each on June 15, 2022. The options will vest over four years while the RSUs will vest over three years. This move follows Nasdaq Listing Rule 5635(c)(4) and demonstrates uniQure's commitment to attracting talent to advance their gene therapy initiatives.

Positive

• Equity awards granted to 22 employees may enhance talent retention.
• The issuance of 39,500 RSUs and options signals potential growth and stability.

Negative

• None.

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, June 22, 2022 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by uniQure N.V. (NASDAQ: QURE), please note that all the numbers have been updated. The corrected release follows:

uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the Company granted equity awards to 22 employees as a material inducement to commencing their employment. The equity grants were approved by the Company’s board of directors on June 15, 2022 (the “Grant Date”) in accordance with Nasdaq Listing Rule 5635(c)(4).

In the aggregate, the employees received 39,500 restricted stock units (“RSUs”) and options to purchase 27,500 ordinary shares of uniQure. Each option has an exercise price of $14.08 per share, the closing price per ordinary share as reported by Nasdaq on June 15, 2022. Each option has a ten-year term and will vest over four years, with 25% of the original number of shares vesting on the first anniversary of the grant date and an additional 6.25% of the shares vesting in approximately equal quarterly installments over the twelve successive quarters following the first anniversary. The RSUs will vest over three years, with one-third of the RSUs vesting annually on each successive anniversary of the Grant Date. The vesting of each grant of options and RSUs is subject to the employee’s continued service with the Company through the applicable vesting dates.

About uniQure
uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary gene therapies to treat patients with hemophilia B, Huntington's disease, refractory temporal lobe epilepsy, Fabry disease, and other diseases. www.uniQure.com

uniQure Contacts:

FOR INVESTORS:		FOR MEDIA:
Maria E. Cantor	Chiara Russo	Tom Malone
Direct: 339-970-7536	Direct: 617-306-9137	Direct: 339-970-7558
Mobile: 617-680-9452	Mobile: 617-306-9137	Mobile: 339-223-8541
m.cantor@uniQure.com	c.russo@uniQure.com	t.malone@uniQure.com

FAQ

What equity awards were granted by uniQure on June 15, 2022?

uniQure granted 39,500 restricted stock units and options for 27,500 ordinary shares to 22 employees.

What is the exercise price for the options granted by uniQure?

The exercise price for the options is $14.08 per share.

How long will the options and RSUs vest at uniQure?

The options will vest over four years, while the RSUs will vest over three years.

What Nasdaq rule did uniQure follow for the equity grants?

uniQure's equity grants were made in accordance with Nasdaq Listing Rule 5635(c)(4).